We encountered an unexpected error, we encourage you to try again later.
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.
To gain access please enter your professional information within your account.
Should you need further support updating your account information, please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
All samples available online to you are included below. Availability is updated periodically.
Savings cards will be shipped with Product Samples, if applicable.
Use your mouse, finger, or stylus to sign below.
I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.
We have received your order and are getting it ready
Download available co-pay cards and patient savings offers across select Pfizer products.
Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.
Changes you have made will not be saved.
This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
cHL post-auto-HSCT consolidation
CD30 is a key biomarker in classical Hodgkin lymphoma and certain peripheral T-cell lymphomas.1
ADCETRIS is part of a class of therapy known as antibody drug conjugates and is designed to target cells expressing CD30.1
See how ADCETRIS targets cells expressing CD30.1
Nonclinical data suggest that the anticancer activity of ADCETRIS acts via CD30-directed cytotoxicity and antibody-dependent cellular phagocytosis (ADCP). ADCETRIS can also harm normal cells.1
The activity of ADCETRIS regardless of CD30 expression may be explainable by several factors and secondary mechanisms including, but not limited to2-7:
CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of systemic anaplastic large cell lymphoma (sALCL) cells, and on Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL). CD30 is variably expressed in other peripheral T-cell lymphomas.1
CD30 is expressed in more than 98% of all cases of cHL.8
| cHL Subtype | Description | CD30 Expression |
|---|---|---|
| Nodular sclerosis cHL | Characterized by collagen bands that surround at least 1 nodule and by HRS cells with lacunar-type morphology9 | 94%10 |
| Mixed cellularity cHL | Characterized by classic HRS cells in a diffuse mixed inflammatory background11 | 100%10 |
| Lymphocyte-depleted cHL | A diffuse form of cHL rich in HRS cells and/or depleted of non-neoplastic lymphocytes. Histiocytes are usually abundant12 | 100%10 |
| Lymphocyte-rich cHL | Characterized by scattered HRS cells and a nodular or diffuse cellular background consisting of small lymphocytes, with an absence of neutrophils and eosinophils13 | 100%10 |
There are approximately 30 different subtypes of CD30-expressing PTCLs14
| PTCL Subtype | Description | CD30 Expression |
|---|---|---|
| Systemic anaplastic large cell lymphoma (sALCL), ALK+/- | Large lymphoid cells with abundant cytoplasm and pleomorphic nuclei; expresses CD30 and may or may not express ALK protein15,16 | 100%17 |
| Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) | Heterogeneous category of nodal and extranodal mature T-cell lymphomas that do not correspond to any specifically defined entities of mature T-cell lymphoma18 | 59%19 |
| Angioimmunoblastic T‑cell lymphoma (AITL) | Neoplasm of mature T follicular helper cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes20 | 76%19 |
| Adult T-cell leukemia lymphoma (ATLL) | Mature T-cell neoplasm most often composed of highly pleomorphic lymphoid cells; usually widely disseminated; caused by the human retrovirus HTLV-121 | 36%-56%22-24 |
| Enteropathy-associated T-cell lymphoma (EATL) | Neoplasm of intraepithelial T-cells occurring in individuals with celiac disease; exhibits varying degrees of cellular pleomorphism25 | 54%19 |
| Extranodal natural killer (NK)/T-cell lymphoma | Characterized by vascular damage and destruction, prominent necrosis, cytotoxic phenotype, and association with Epstein-Barr virus26 | 52%-75%19,27 |
ADCETRIS+CHP is approved for any level of CD30 expression.
Make sure no appropriate patient is missed.1
ALK = anaplastic lymphoma kinase; HTLV-1 = human T-lymphotropic virus type 1.
Percentage stated
Any CD30 expression (%) renders patients eligible for ADCETRIS1

Binary results
Qualitative reporting may miss patients with CD30 expression who qualify for ADCETRIS1,28,29
To report an adverse event, please call 1‑800‑438‑1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2026 Pfizer Inc. All rights reserved.
ADCETRIS® (brentuximab vedotin) is indicated for the treatment of:
Previously untreated Stage III/IV cHL
Previously untreated high risk cHL
cHL post-auto-HSCT consolidation
Relapsed cHL
Previously untreated sALCL or other CD30-expressing PTCL
Relapsed sALCL
Relapsed pcALCL or CD30-expressing MF
Relapsed and Refractory Large B-Cell Lymphoma (LBCL)
Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.
BOXED WARNING
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.
CONTRAINDICATION
Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).
WARNINGS AND PRECAUTIONS
Peripheral neuropathy (PN): ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.
Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.
Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1 week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.
Administer G-CSF primary prophylaxis beginning with Cycle 1 for adult patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL or relapsed or refractory LBCL and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.
Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays, reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.
Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.
Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.
Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.
Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.
Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.
PML: Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.
Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.
Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.
Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.
Hyperglycemia: Serious cases, such as new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.
Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS treatment and for 4 months after the last dose of ADCETRIS.
ADVERSE REACTIONS
The most common adverse reactions (≥20%) in adult patients are peripheral neuropathy, nausea, fatigue, musculoskeletal pain, constipation, diarrhea, vomiting, pyrexia, upper respiratory tract infection, mucositis, abdominal pain, and rash. The most common laboratory abnormalities (≥20%) in adult patients are decreased neutrophils, increased creatinine, decreased hemoglobin, decreased lymphocytes, increased glucose, increased ALT, and increased AST.
The most common Grade ≥3 adverse reactions (≥5%) in combination with AVEPC in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.
DRUG INTERACTIONS
Concomitant use of strong CYP3A4 inhibitors has the potential to affect the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.
USE IN SPECIAL POPULATIONS
Lactation: Breastfeeding is not recommended during ADCETRIS treatment.